Screener
Recursion Pharmaceuticals, Inc. RXRX Q2 2026 earnings
Reported August 5, 2026 · Before market open
Revenue$7.3MMiss by $3.7M
EPS-$0.25Miss by $0.01
Revenue estimate$11.0M
EPS estimate-$0.24
“The advancement of the first unexplored neuroscience target from our collaboration with Roche and Genentech into an early discovery program is an important proof point. Finding new targets in neuroscience has historically been challenging, and this milestone highlights our ability to uncover novel biology in areas where conventional approaches have struggled. We believe that combining disease-relevant data at scale, foundation models, an end-to-end learning system, and deep scientific collaboration can uncover new biology in ways that were not previously possible.”
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$14.2M
EPS estimate-$0.24
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Recursion Pharmaceuticals, Inc. report Q2 2026 earnings?
- Recursion Pharmaceuticals, Inc. (RXRX) reported Q2 2026 earnings on August 5, 2026 before market open.
- What were Recursion Pharmaceuticals, Inc.'s Q2 2026 revenue and EPS?
- Recursion Pharmaceuticals, Inc. reported revenue of $7.3M and eps of $-0.25 for Q2 2026.
- Did Recursion Pharmaceuticals, Inc. beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $11.0M by $3.7M. EPS missed the consensus estimate of $-0.24 by $0.01.
- How did Recursion Pharmaceuticals, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 61.8% from $19.1M a year earlier and eps grew 39.0% from $-0.41.
- Where can I find Recursion Pharmaceuticals, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001601830-26-000097) and the 10-Q periodic report (0001601830-26-000098) directly on SEC EDGAR. The filing index links above go to sec.gov.
